Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Oct 29, 2020 3:55pm
140 Views
Post# 31807405

RE:RE:RE:RE:RE:RE:I sure hope Harrison gets back on the call

RE:RE:RE:RE:RE:RE:I sure hope Harrison gets back on the callOne other point I forgot, the Madrigal CMO spoke about presenting some 16-24 weeks interim reads in their upcoming trials soon.  I guess that's one of the papers Harrison is on.  It seems to me that it's becoming pretty standard practice to have some kind of interim reads so I hope THTX includes that in their trial. 

Maybe not 16 weeks, but perhaps you can do a 26 and 52 week read so there's something out there.  Of course, it's a double-edge sword but that seems to be what others are doing more often than not doing.

Also, how come I know who Harrison is and Levesque didn't?  Not a good sign!  I'm sure Marsolais and Grinspoon did, but still.  He needs to crank up his own knowledge base.  I would have thought from his Pfizer days he would have read the name in one of the journals he reads. 
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse